By Tess Stynes
Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and H.
Lundbeck A/S (HLUYY, LUN.KO) said their Azilect treatment for
Parkinson's disease in combination with dopamine agonist therapy
met its primary endpoint in an 18-week study.
The study data "continue to clarify the clinical profile of
Azilect and the role it plays in helping to meet the needs of those
living with [Parkinson's disease], at multiple points in the
progression of their disease," said Dr. Michael Hayden, president
of global research and development and chief scientific officer at
Teva.
Azilect--or rasagiline--is indicated for the treatment of the
signs and symptoms of Parkinson's disease both as initial
standalone therapy and in combination with levodopa later in the
disease.
The study data will be presented Wednesday at the 65th American
Academy of Neurology Annual Meeting in San Diego.
Teva's American depositary shares were up 26 cents at $40.25 in
premarket trading. H. Lundbeck's ADSs closed Tuesday at $17.46 and
were inactive premarket.
Write to Tess Stynes at Tess.Stynes@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires